25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CrystalGenomics Inc
Buy, Hold or Sell?

Let's analyze CrystalGenomics Inc together

I guess you are interested in CrystalGenomics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CrystalGenomics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CrystalGenomics Inc

I send you an email if I find something interesting about CrystalGenomics Inc.

1. Quick Overview

1.1. Quick analysis of CrystalGenomics Inc (30 sec.)










1.2. What can you expect buying and holding a share of CrystalGenomics Inc? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
₩1,662.13
Expected worth in 1 year
₩1,191.88
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
₩-470.25
Return On Investment
-18.6%

For what price can you sell your share?

Current Price per Share
₩2,530.00
Expected price per share
₩2,015 - ₩3,170
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of CrystalGenomics Inc (5 min.)




Live pricePrice per Share (EOD)
₩2,530.00

2.2. Growth of CrystalGenomics Inc (5 min.)




Is CrystalGenomics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$89m$126.9m-$24.6m-24.0%

How much money is CrystalGenomics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.6m-$9.3m$3.7m65.8%
Net Profit Margin-286.7%-167.3%--

How much money comes from the company's main activities?

2.3. Financial Health of CrystalGenomics Inc (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of CrystalGenomics Inc?

Welcome investor! CrystalGenomics Inc's management wants to use your money to grow the business. In return you get a share of CrystalGenomics Inc.

First you should know what it really means to hold a share of CrystalGenomics Inc. And how you can make/lose money.

Speculation

The Price per Share of CrystalGenomics Inc is ₩2,530. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of CrystalGenomics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in CrystalGenomics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩1,662.13. Based on the TTM, the Book Value Change Per Share is ₩-117.56 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-200.72 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of CrystalGenomics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.130.0%-0.070.0%-0.130.0%-0.080.0%-0.040.0%
Usd Book Value Change Per Share-0.090.0%-0.080.0%-0.140.0%-0.100.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.090.0%-0.080.0%-0.140.0%-0.100.0%0.010.0%
Usd Price Per Share1.88-2.13-2.49-5.74-9.17-
Price to Earnings Ratio-3.61--3.05--8.42-27.73-18.76-
Price-to-Total Gains Ratio-20.51--11.92--32.32--14.65--522.18-
Price to Book Ratio1.62-1.61-1.41-2.37-5.41-
Price-to-Total Gains Ratio-20.51--11.92--32.32--14.65--522.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.771
Number of shares564
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.08-0.10
Usd Total Gains Per Share-0.08-0.10
Gains per Quarter (564 shares)-46.41-54.75
Gains per Year (564 shares)-185.66-219.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-186-1968-227-229
20-371-38215-453-448
30-557-56823-680-667
40-743-75430-906-886
50-928-94038-1133-1105
60-1114-112646-1360-1324
70-1300-131253-1586-1543
80-1485-149861-1813-1762
90-1671-168469-2039-1981
100-1857-187076-2266-2200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%5.015.00.025.0%10.020.010.025.0%10.020.016.021.7%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%18.022.00.045.0%22.024.00.047.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%3.00.017.015.0%4.00.036.010.0%4.00.042.08.7%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%18.022.00.045.0%22.024.00.047.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CrystalGenomics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---131.137-117.564-10%-200.722+53%-143.496+9%16.068-916%
Book Value Per Share--1662.1311921.143-13%2599.530-36%3207.246-48%2802.593-41%
Current Ratio--0.7940.842-6%1.228-35%1.716-54%2.504-68%
Debt To Asset Ratio--0.4630.440+5%0.4640%0.435+6%0.384+21%
Debt To Equity Ratio--0.8630.784+10%0.891-3%0.830+4%0.685+26%
Dividend Per Share----0%-0%4.821-100%2.644-100%
Eps---186.207-103.980-44%-184.217-1%-111.092-40%-56.007-70%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.750+33%
Market Cap102345331000.000-101%205901861670.000232252707566.250-11%250935237125.000-18%418542738758.227-51%574313191239.820-64%
Net Profit Margin---6.538-2.867-56%-1.673-74%-1.358-79%-0.849-87%
Operating Margin----0%-0.2840%-0.3090%-0.3930%
Operating Ratio--1.7123.795-55%1.593+7%1.615+6%1.376+24%
Pb Ratio1.522-6%1.6181.612+0%1.410+15%2.371-32%5.405-70%
Pe Ratio-3.397+6%-3.612-3.045-16%-8.423+133%27.732-113%18.765-119%
Price Per Share2530.000-6%2690.0003048.750-12%3561.250-24%8203.334-67%13106.666-79%
Price To Free Cash Flow Ratio----3.6840%-6.0700%-18.0960%-19.3210%
Price To Total Gains Ratio-19.293+6%-20.513-11.916-42%-32.324+58%-14.655-29%-522.184+2446%
Quick Ratio---0.250-100%1.660-100%2.067-100%1.375-100%
Return On Assets---0.060-0.040-34%-0.038-37%-0.024-59%-0.013-79%
Return On Equity---0.112-0.067-40%-0.079-30%-0.049-56%-0.025-78%
Total Gains Per Share---131.137-117.564-10%-200.722+53%-138.675+6%18.712-801%
Usd Book Value--89057653.300102328310.788-13%126929406.531-30%125441006.416-29%96807529.102-8%
Usd Book Value Change Per Share---0.092-0.082-10%-0.141+53%-0.100+9%0.011-916%
Usd Book Value Per Share--1.1631.345-13%1.820-36%2.245-48%1.962-41%
Usd Dividend Per Share----0%-0%0.003-100%0.002-100%
Usd Eps---0.130-0.073-44%-0.129-1%-0.078-40%-0.039-70%
Usd Free Cash Flow----7744824.6420%-8052851.3500%-5705875.2930%-3084338.9050%
Usd Market Cap71641731.700-101%144131303.169162576895.296-11%175654665.988-18%292979917.131-51%402019233.868-64%
Usd Price Per Share1.771-6%1.8832.134-12%2.493-24%5.742-67%9.175-79%
Usd Profit---9977026.500-5643866.764-43%-9357081.024-6%-5251051.554-47%-2636413.740-74%
Usd Revenue--1526002.800-779511.010+151%7087849.519-78%8711948.804-82%5325189.010-71%
Usd Total Gains Per Share---0.092-0.082-10%-0.141+53%-0.097+6%0.013-801%
 EOD+3 -4MRQTTM+4 -22YOY+8 -185Y+7 -2110Y+5 -24

3.3 Fundamental Score

Let's check the fundamental score of CrystalGenomics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.397
Price to Book Ratio (EOD)Between0-11.522
Net Profit Margin (MRQ)Greater than0-6.538
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.794
Debt to Asset Ratio (MRQ)Less than10.463
Debt to Equity Ratio (MRQ)Less than10.863
Return on Equity (MRQ)Greater than0.15-0.112
Return on Assets (MRQ)Greater than0.05-0.060
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of CrystalGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.720
Ma 20Greater thanMa 502,571.250
Ma 50Greater thanMa 1002,438.300
Ma 100Greater thanMa 2002,492.700
OpenGreater thanClose2,590.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About CrystalGenomics Inc

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Fundamental data was last updated by Penke on 2024-11-18 20:12:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit CrystalGenomics Inc earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • A Net Profit Margin of -653.8% means that ₩-6.54 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CrystalGenomics Inc:

  • The MRQ is -653.8%. The company is making a huge loss. -2
  • The TTM is -286.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-653.8%TTM-286.7%-367.1%
TTM-286.7%YOY-167.3%-119.4%
TTM-286.7%5Y-135.8%-150.9%
5Y-135.8%10Y-84.9%-50.9%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-653.8%9.8%-663.6%
TTM-286.7%9.5%-296.2%
YOY-167.3%9.9%-177.2%
5Y-135.8%12.9%-148.7%
10Y-84.9%12.6%-97.5%
4.3.1.2. Return on Assets

Shows how efficient CrystalGenomics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • -6.0% Return on Assets means that CrystalGenomics Inc generated ₩-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CrystalGenomics Inc:

  • The MRQ is -6.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.0%TTM-4.0%-2.1%
TTM-4.0%YOY-3.8%-0.2%
TTM-4.0%5Y-2.4%-1.5%
5Y-2.4%10Y-1.3%-1.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.0%3.6%-9.6%
TTM-4.0%3.5%-7.5%
YOY-3.8%5.3%-9.1%
5Y-2.4%5.9%-8.3%
10Y-1.3%4.9%-6.2%
4.3.1.3. Return on Equity

Shows how efficient CrystalGenomics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • -11.2% Return on Equity means CrystalGenomics Inc generated ₩-0.11 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CrystalGenomics Inc:

  • The MRQ is -11.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.2%TTM-6.7%-4.5%
TTM-6.7%YOY-7.9%+1.2%
TTM-6.7%5Y-4.9%-1.8%
5Y-4.9%10Y-2.5%-2.4%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.2%4.6%-15.8%
TTM-6.7%4.6%-11.3%
YOY-7.9%8.2%-16.1%
5Y-4.9%9.1%-14.0%
10Y-2.5%10.3%-12.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CrystalGenomics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient CrystalGenomics Inc is operating .

  • Measures how much profit CrystalGenomics Inc makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CrystalGenomics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-28.4%+28.4%
TTM-5Y-30.9%+30.9%
5Y-30.9%10Y-39.3%+8.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY-28.4%12.4%-40.8%
5Y-30.9%8.6%-39.5%
10Y-39.3%12.1%-51.4%
4.3.2.2. Operating Ratio

Measures how efficient CrystalGenomics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.71 means that the operating costs are ₩1.71 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of CrystalGenomics Inc:

  • The MRQ is 1.712. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.795. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.712TTM3.795-2.082
TTM3.795YOY1.593+2.202
TTM3.7955Y1.615+2.179
5Y1.61510Y1.376+0.240
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7121.225+0.487
TTM3.7951.220+2.575
YOY1.5931.311+0.282
5Y1.6151.249+0.366
10Y1.3761.240+0.136
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CrystalGenomics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if CrystalGenomics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 0.79 means the company has ₩0.79 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of CrystalGenomics Inc:

  • The MRQ is 0.794. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.842. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.794TTM0.842-0.048
TTM0.842YOY1.228-0.386
TTM0.8425Y1.716-0.874
5Y1.71610Y2.504-0.788
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7942.213-1.419
TTM0.8422.234-1.392
YOY1.2282.028-0.800
5Y1.7162.199-0.483
10Y2.5041.995+0.509
4.4.3.2. Quick Ratio

Measures if CrystalGenomics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CrystalGenomics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.250-0.250
TTM0.250YOY1.660-1.411
TTM0.2505Y2.067-1.817
5Y2.06710Y1.375+0.692
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.926-0.926
TTM0.2500.973-0.723
YOY1.6601.515+0.145
5Y2.0671.591+0.476
10Y1.3751.399-0.024
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CrystalGenomics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of CrystalGenomics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare CrystalGenomics Inc to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.46 means that CrystalGenomics Inc assets are financed with 46.3% credit (debt) and the remaining percentage (100% - 46.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CrystalGenomics Inc:

  • The MRQ is 0.463. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.440. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.463TTM0.440+0.023
TTM0.440YOY0.464-0.024
TTM0.4405Y0.435+0.005
5Y0.43510Y0.384+0.051
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4630.345+0.118
TTM0.4400.339+0.101
YOY0.4640.333+0.131
5Y0.4350.315+0.120
10Y0.3840.339+0.045
4.5.4.2. Debt to Equity Ratio

Measures if CrystalGenomics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 86.3% means that company has ₩0.86 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CrystalGenomics Inc:

  • The MRQ is 0.863. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.784. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.863TTM0.784+0.079
TTM0.784YOY0.891-0.107
TTM0.7845Y0.830-0.047
5Y0.83010Y0.685+0.145
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8630.547+0.316
TTM0.7840.547+0.237
YOY0.8910.499+0.392
5Y0.8300.476+0.354
10Y0.6850.548+0.137
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings CrystalGenomics Inc generates.

  • Above 15 is considered overpriced but always compare CrystalGenomics Inc to the Pharmaceuticals industry mean.
  • A PE ratio of -3.61 means the investor is paying ₩-3.61 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CrystalGenomics Inc:

  • The EOD is -3.397. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.612. Based on the earnings, the company is expensive. -2
  • The TTM is -3.045. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.397MRQ-3.612+0.215
MRQ-3.612TTM-3.045-0.566
TTM-3.045YOY-8.423+5.378
TTM-3.0455Y27.732-30.778
5Y27.73210Y18.765+8.968
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-3.39727.863-31.260
MRQ-3.61229.844-33.456
TTM-3.04527.532-30.577
YOY-8.42323.102-31.525
5Y27.73227.577+0.155
10Y18.76529.248-10.483
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CrystalGenomics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3.684+3.684
TTM-3.684YOY-6.070+2.386
TTM-3.6845Y-18.096+14.412
5Y-18.09610Y-19.321+1.225
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.531-29.531
TTM-3.68429.447-33.131
YOY-6.07026.360-32.430
5Y-18.09631.734-49.830
10Y-19.32134.357-53.678
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of CrystalGenomics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 1.62 means the investor is paying ₩1.62 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of CrystalGenomics Inc:

  • The EOD is 1.522. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.618. Based on the equity, the company is underpriced. +1
  • The TTM is 1.612. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.522MRQ1.618-0.096
MRQ1.618TTM1.612+0.006
TTM1.612YOY1.410+0.203
TTM1.6125Y2.371-0.759
5Y2.37110Y5.405-3.034
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.5224.659-3.137
MRQ1.6183.381-1.763
TTM1.6123.209-1.597
YOY1.4102.597-1.187
5Y2.3713.278-0.907
10Y5.4054.179+1.226
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Operating Income  -7,197,1141,676,640-5,520,474-8,855,873-14,376,3478,277,633-6,098,7146,412,267313,553



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets237,006,668
Total Liabilities109,781,449
Total Stockholder Equity127,225,219
 As reported
Total Liabilities 109,781,449
Total Stockholder Equity+ 127,225,219
Total Assets = 237,006,668

Assets

Total Assets237,006,668
Total Current Assets49,373,624
Long-term Assets187,633,044
Total Current Assets
Total Current Assets  (as reported)49,373,624
Total Current Assets  (calculated)0
+/- 49,373,624
Long-term Assets
Long-term Assets  (as reported)187,633,044
Long-term Assets  (calculated)0
+/- 187,633,044

Liabilities & Shareholders' Equity

Total Current Liabilities62,181,508
Long-term Liabilities47,599,941
Total Stockholder Equity127,225,219
Total Current Liabilities
Total Current Liabilities  (as reported)62,181,508
Total Current Liabilities  (calculated)0
+/- 62,181,508
Long-term Liabilities
Long-term Liabilities  (as reported)47,599,941
Long-term Liabilities  (calculated)0
+/- 47,599,941
Total Stockholder Equity
Total Stockholder Equity (as reported)127,225,219
Total Stockholder Equity (calculated)0
+/- 127,225,219
Other
Common Stock Shares Outstanding 76,543
Net Invested Capital 127,225,219
Net Working Capital -12,807,884



6.3. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
54,861,286
54,034,828
85,036,410
88,769,402
87,149,330
102,050,490
104,700,352
106,051,985
104,903,106
108,939,514
108,435,626
127,284,550
125,307,683
125,068,657
126,580,796
128,666,439
136,661,983
125,081,854
124,615,814
119,465,138
116,793,464
120,894,065
181,731,743
256,919,699
256,418,858
255,197,988
301,630,414
379,189,387
380,405,741
376,424,419
321,744,069
316,960,077
312,070,954
310,909,013
311,060,953
332,926,810
326,422,318
339,994,239
332,398,864
322,613,064
337,936,874
366,719,996
333,561,580
243,115,542
236,309,116
237,006,668
237,006,668236,309,116243,115,542333,561,580366,719,996337,936,874322,613,064332,398,864339,994,239326,422,318332,926,810311,060,953310,909,013312,070,954316,960,077321,744,069376,424,419380,405,741379,189,387301,630,414255,197,988256,418,858256,919,699181,731,743120,894,065116,793,464119,465,138124,615,814125,081,854136,661,983128,666,439126,580,796125,068,657125,307,683127,284,550108,435,626108,939,514104,903,106106,051,985104,700,352102,050,49087,149,33088,769,40285,036,41054,034,82854,861,286
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,819,067
48,377,679
34,493,003
32,011,253
33,762,054
91,458,752
166,757,824
161,429,748
157,991,556
175,096,807
238,210,422
233,489,977
227,288,504
142,916,773
164,043,039
170,297,278
162,013,187
153,468,844
144,965,453
117,774,121
129,835,106
119,605,228
98,853,917
95,872,500
121,752,827
102,390,110
56,651,954
35,663,715
49,373,624
49,373,62435,663,71556,651,954102,390,110121,752,82795,872,50098,853,917119,605,228129,835,106117,774,121144,965,453153,468,844162,013,187170,297,278164,043,039142,916,773227,288,504233,489,977238,210,422175,096,807157,991,556161,429,748166,757,82491,458,75233,762,05432,011,25334,493,00348,377,67947,819,06700000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,797,409
31,014,623
21,677,944
17,303,804
18,042,019
47,238,111
34,816,669
32,854,848
42,704,357
59,783,158
22,669,287
17,565,495
21,483,266
29,755,568
47,224,413
64,501,130
31,846,585
39,230,296
458
458
458
458
29,963,646
100
100
49,820,043
23,011,318
23,323,455
0
023,323,45523,011,31849,820,04310010029,963,64645845845845839,230,29631,846,58564,501,13047,224,41329,755,56821,483,26617,565,49522,669,28759,783,15842,704,35732,854,84834,816,66947,238,11118,042,01917,303,80421,677,94431,014,62328,797,40900000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,525,033
7,934,999
6,967,413
8,003,313
12,395,453
8,792,191
10,220,000
23,220,000
25,450,000
27,492,480
0
0
0
83,039,724
91,926,085
82,844,315
106,675,995
87,837,443
91,594,756
70,278,843
61,688,897
64,269,604
51,954,415
39,707,148
37,620,881
35,713,534
28,398,419
6,764,872
0
06,764,87228,398,41935,713,53437,620,88139,707,14851,954,41564,269,60461,688,89770,278,84391,594,75687,837,443106,675,99582,844,31591,926,08583,039,72400027,492,48025,450,00023,220,00010,220,0008,792,19112,395,4538,003,3136,967,4137,934,99914,525,03300000000000000000
       Net Receivables 
831,794
446,858
513,860
4,090,130
316,544
486,448
699,157
3,057,966
3,412,533
2,968,373
0
9,311,393
0
0
0
6,852,870
6,575,956
0
5,597,739
3,059,721
2,899,390
1,823,973
2,251,420
7,275,139
7,352,454
10,126,517
6,946,955
47,659,520
53,090,447
51,927,893
8,725,271
13,376,908
11,275,370
9,691,889
11,763,532
12,317,998
10,198,571
8,025,331
7,790,834
7,836,106
5,422,328
6,245,263
4,411,908
150,336
8,027
0
08,027150,3364,411,9086,245,2635,422,3287,836,1067,790,8348,025,33110,198,57112,317,99811,763,5329,691,88911,275,37013,376,9088,725,27151,927,89353,090,44747,659,5206,946,95510,126,5177,352,4547,275,1392,251,4201,823,9732,899,3903,059,7215,597,73906,575,9566,852,8700009,311,39302,968,3733,412,5333,057,966699,157486,448316,5444,090,130513,860446,858831,794
       Inventory 
0
0
0
0
0
0
223,893
107,338
129,489
163,714
401,938
1,269,987
1,632,851
1,571,696
3,114,821
3,994,490
4,666,008
460,757
338,840
517,419
368,514
303,714
303,714
449,046
383,130
226,800
13,848,696
40,207,040
43,140,529
48,484,901
15,448,808
10,009,874
10,475,855
12,765,180
13,370,140
8,577,795
10,180,505
12,516,772
12,055,964
5,677,341
8,650,553
11,156,263
6,358,562
1,554,792
1,656,067
0
01,656,0671,554,7926,358,56211,156,2638,650,5535,677,34112,055,96412,516,77210,180,5058,577,79513,370,14012,765,18010,475,85510,009,87415,448,80848,484,90143,140,52940,207,04013,848,696226,800383,130449,046303,714303,714368,514517,419338,840460,7574,666,0083,994,4903,114,8211,571,6961,632,8511,269,987401,938163,714129,489107,338223,893000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
223,759,146
242,064,374
244,967,169
231,171,471
186,463,587
200,645,401
187,633,044
187,633,044200,645,401186,463,587231,171,471244,967,169242,064,374223,759,146000000000000000000000000000000000000000
       Property Plant Equipment 
8,881,456
8,663,346
8,522,657
13,864,110
13,642,423
13,421,475
13,242,921
13,142,576
12,943,348
12,737,096
12,645,418
24,043,282
23,848,752
23,590,476
23,653,545
24,477,377
24,587,259
13,925,768
13,713,184
23,454,301
23,351,327
23,156,489
23,058,810
22,883,481
22,723,362
22,603,783
40,536,726
76,066,528
76,732,688
77,827,232
41,917,894
43,143,058
44,672,381
48,187,981
50,442,829
86,370,551
88,576,485
91,644,804
94,761,243
100,173,544
104,539,260
112,811,064
109,985,324
95,589,668
97,533,640
0
097,533,64095,589,668109,985,324112,811,064104,539,260100,173,54494,761,24391,644,80488,576,48586,370,55150,442,82948,187,98144,672,38143,143,05841,917,89477,827,23276,732,68876,066,52840,536,72622,603,78322,723,36222,883,48123,058,81023,156,48923,351,32723,454,30113,713,18413,925,76824,587,25924,477,37723,653,54523,590,47623,848,75224,043,28212,645,41812,737,09612,943,34813,142,57613,242,92113,421,47513,642,42313,864,1108,522,6578,663,3468,881,456
       Goodwill 
0
0
0
3,629,100
0
0
0
2,332,221
2,332,221
0
0
4,993,108
0
0
0
4,985,834
0
0
2,332,221
2,332,221
2,332,221
2,332,221
2,332,221
0
0
0
8,977,177
5,733,082
5,733,082
5,733,082
5,733,082
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
2,026,277
0
0
14,106,555
0
014,106,555002,026,2772,026,2772,026,2772,026,2772,026,2772,026,2772,026,2772,026,2772,026,2772,026,2772,026,2775,733,0825,733,0825,733,0825,733,0828,977,1770002,332,2212,332,2212,332,2212,332,2212,332,221004,985,8340004,993,108002,332,2212,332,2210003,629,100000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,015,884
49,307,630
48,345,741
48,351,812
48,492,006
51,806,113
53,724,480
58,632,677
64,155,929
59,043,398
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000059,043,39864,155,92958,632,67753,724,48051,806,11348,492,00648,351,81248,345,74149,307,63050,015,88400000000000000000
       Intangible Assets 
9,504,236
9,382,266
9,260,894
6,990,190
6,865,387
6,743,912
6,621,553
5,207,315
5,092,414
4,974,930
4,857,474
7,402,800
7,299,658
7,226,051
7,125,088
7,035,629
7,487,241
4,166,152
4,070,921
4,027,044
3,934,068
1,504,219
1,438,526
1,338,972
1,239,485
1,163,831
7,497,034
11,789,744
11,463,531
13,231,283
9,883,266
9,481,876
9,092,397
8,772,237
8,411,198
8,119,575
7,876,459
7,584,890
7,293,321
6,404,825
6,182,978
5,411,648
1,952,778
1,679,849
1,561,336
0
01,561,3361,679,8491,952,7785,411,6486,182,9786,404,8257,293,3217,584,8907,876,4598,119,5758,411,1988,772,2379,092,3979,481,8769,883,26613,231,28311,463,53111,789,7447,497,0341,163,8311,239,4851,338,9721,438,5261,504,2193,934,0684,027,0444,070,9214,166,1527,487,2417,035,6297,125,0887,226,0517,299,6587,402,8004,857,4744,974,9305,092,4145,207,3156,621,5536,743,9126,865,3876,990,1909,260,8949,382,2669,504,236
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,355,244
-1,444,757
0
0
7,473,037
688,942
0
0688,9427,473,03700-1,444,7573,355,244000000000000000000000000000000000000000
> Total Liabilities 
32,790,083
33,111,985
58,439,946
52,605,846
53,325,353
60,811,829
48,629,082
51,024,326
51,365,326
51,268,500
40,782,099
53,645,553
49,319,063
49,651,949
41,591,268
45,401,565
55,370,855
28,725,809
27,764,330
27,878,221
25,259,912
24,644,787
24,656,553
72,452,650
70,593,274
71,864,140
122,129,121
230,140,805
238,999,228
229,488,979
113,610,362
102,203,286
96,169,222
105,134,379
107,790,660
125,089,236
122,862,090
142,136,369
139,094,256
134,337,324
154,251,836
206,674,487
158,609,501
97,822,548
99,046,203
109,781,449
109,781,44999,046,20397,822,548158,609,501206,674,487154,251,836134,337,324139,094,256142,136,369122,862,090125,089,236107,790,660105,134,37996,169,222102,203,286113,610,362229,488,979238,999,228230,140,805122,129,12171,864,14070,593,27472,452,65024,656,55324,644,78725,259,91227,878,22127,764,33028,725,80955,370,85545,401,56541,591,26849,651,94949,319,06353,645,55340,782,09951,268,50051,365,32651,024,32648,629,08260,811,82953,325,35352,605,84658,439,94633,111,98532,790,083
   > Total Current Liabilities 
30,096,996
30,529,641
25,378,803
6,119,522
5,612,240
5,459,695
5,898,180
31,778,600
31,633,256
31,056,417
11,948,667
38,350,978
31,581,669
32,893,591
35,278,246
40,236,077
50,374,781
25,434,195
24,518,352
16,967,136
14,304,248
13,520,209
13,431,685
10,258,104
9,851,315
10,029,141
53,068,671
134,598,357
139,855,116
131,562,058
96,024,603
71,362,645
64,819,052
60,885,512
63,549,270
66,513,390
64,873,000
62,171,383
64,211,875
80,836,746
92,011,010
155,293,791
109,456,710
55,547,659
57,507,535
62,181,508
62,181,50857,507,53555,547,659109,456,710155,293,79192,011,01080,836,74664,211,87562,171,38364,873,00066,513,39063,549,27060,885,51264,819,05271,362,64596,024,603131,562,058139,855,116134,598,35753,068,67110,029,1419,851,31510,258,10413,431,68513,520,20914,304,24816,967,13624,518,35225,434,19550,374,78140,236,07735,278,24632,893,59131,581,66938,350,97811,948,66731,056,41731,633,25631,778,6005,898,1805,459,6955,612,2406,119,52225,378,80330,529,64130,096,996
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,257,450
15,694,960
6,432,470
6,369,980
6,307,490
6,245,000
6,245,000
6,245,000
6,245,000
41,705,760
41,908,929
45,436,983
43,706,630
37,680,000
37,680,000
37,680,000
36,045,000
38,045,000
38,045,000
38,045,000
38,045,000
38,045,000
44,145,000
55,745,000
41,930,000
0
0
0
0
000041,930,00055,745,00044,145,00038,045,00038,045,00038,045,00038,045,00038,045,00036,045,00037,680,00037,680,00037,680,00043,706,63045,436,98341,908,92941,705,7606,245,0006,245,0006,245,0006,245,0006,307,4906,369,9806,432,47015,694,96021,257,45000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,257,450
15,694,960
6,432,470
6,369,980
6,307,490
6,245,000
6,245,000
6,245,000
6,245,000
6,855,760
0
0
0
0
0
0
0
0
0
0
0
0
49,458,351
60,005,279
42,326,100
42,739,999
1,960,000
2,940,000
0
02,940,0001,960,00042,739,99942,326,10060,005,27949,458,3510000000000006,855,7606,245,0006,245,0006,245,0006,245,0006,307,4906,369,9806,432,47015,694,96021,257,45000000000000000000
       Accounts payable 
0
0
0
56,970
0
146,114
541,273
1,596,001
921,355
429,747
0
4,005,492
2,073,127
0
0
2,058,127
0
0
245,790
738,975
0
110,463
0
346,057
82,611
0
4,160,664
7,979,082
7,836,065
7,295,362
0
3,463,659
2,766,397
2,309,005
1,961,127
2,111,390
2,945,396
3,634,064
2,760,882
1,853,921
2,100,589
2,994,546
3,147,112
4,324,196
3,440,464
0
03,440,4644,324,1963,147,1122,994,5462,100,5891,853,9212,760,8823,634,0642,945,3962,111,3901,961,1272,309,0052,766,3973,463,65907,295,3627,836,0657,979,0824,160,664082,611346,0570110,4630738,975245,790002,058,127002,073,1274,005,4920429,747921,3551,596,001541,273146,114056,970000
       Other Current Liabilities 
8,548,376
9,106,873
16,517,737
3,563,552
3,137,990
2,814,581
2,956,907
9,682,751
9,491,292
9,112,447
6,548,667
8,584,228
6,788,949
7,293,690
9,096,416
6,177,061
8,712,095
4,239,235
3,377,602
4,595,691
2,734,268
1,745,337
1,829,171
2,527,686
2,383,878
2,596,798
5,124,567
43,197,746
49,671,307
43,898,991
34,065,418
16,636,520
12,578,850
10,183,246
10,414,478
9,193,441
8,425,189
6,197,184
11,443,698
1
1
-2
0
-1
0
0
00-10-21111,443,6986,197,1848,425,1899,193,44110,414,47810,183,24612,578,85016,636,52034,065,41843,898,99149,671,30743,197,7465,124,5672,596,7982,383,8782,527,6861,829,1711,745,3372,734,2684,595,6913,377,6024,239,2358,712,0956,177,0619,096,4167,293,6906,788,9498,584,2286,548,6679,112,4479,491,2929,682,7512,956,9072,814,5813,137,9903,563,55216,517,7379,106,8738,548,376
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,353,289
57,337,479
62,152,465
49,152,790
42,274,890
41,538,669
47,599,941
47,599,94141,538,66942,274,89049,152,79062,152,46557,337,47948,353,289000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,827,943
12,536,573
15,908,358
15,518,482
14,963,319
14,763,252
15,913,878
28,111,289
28,437,445
24,399,170
24,343,086
33,438,258
33,914,220
20,508,039
29,147,436
33,918,902
0
0
0
0
000033,918,90229,147,43620,508,03933,914,22033,438,25824,343,08624,399,17028,437,44528,111,28915,913,87814,763,25214,963,31915,518,48215,908,35812,536,57340,827,94300000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-21,257,450
-15,694,960
-6,432,470
-6,369,980
-6,307,490
-6,245,000
-6,245,000
-6,245,000
-6,245,000
-41,705,760
-41,908,929
-45,436,983
-43,706,630
-37,680,000
-37,680,000
-37,680,000
-36,045,000
-38,045,000
-38,045,000
-38,045,000
-38,045,000
-38,045,000
-43,687,163
-55,308,267
-41,553,570
398,158
304,895
291,421
0
0291,421304,895398,158-41,553,570-55,308,267-43,687,163-38,045,000-38,045,000-38,045,000-38,045,000-38,045,000-36,045,000-37,680,000-37,680,000-37,680,000-43,706,630-45,436,983-41,908,929-41,705,760-6,245,000-6,245,000-6,245,000-6,245,000-6,307,490-6,369,980-6,432,470-15,694,960-21,257,45000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,674,434
4,654,894
4,589,520
4,561,455
3,436,259
3,416,999
0
03,416,9993,436,2594,561,4554,589,5204,654,8944,674,434000000000000000000000000000000000000000
> Total Stockholder Equity
22,071,203
20,922,843
26,596,464
36,163,555
33,823,977
41,238,661
56,071,271
55,027,659
53,537,780
57,671,014
67,653,527
71,940,651
74,291,022
73,882,993
83,517,888
83,158,159
81,430,121
96,356,046
96,851,484
91,586,917
91,533,552
95,633,337
156,604,177
183,776,805
185,135,339
182,643,603
179,501,293
149,048,583
141,406,513
146,935,440
208,133,707
214,756,791
215,901,732
205,774,634
203,270,293
207,837,574
203,560,228
197,857,870
193,304,608
188,275,740
183,685,037
160,045,509
180,559,038
145,292,993
137,372,976
127,225,219
127,225,219137,372,976145,292,993180,559,038160,045,509183,685,037188,275,740193,304,608197,857,870203,560,228207,837,574203,270,293205,774,634215,901,732214,756,791208,133,707146,935,440141,406,513149,048,583179,501,293182,643,603185,135,339183,776,805156,604,17795,633,33791,533,55291,586,91796,851,48496,356,04681,430,12183,158,15983,517,88873,882,99374,291,02271,940,65167,653,52757,671,01453,537,78055,027,65956,071,27141,238,66133,823,97736,163,55526,596,46420,922,84322,071,203
   Common Stock
8,809,568
9,126,208
9,200,679
9,673,496
9,771,467
10,172,753
11,150,295
11,298,487
11,307,916
11,470,927
11,954,887
12,258,475
12,367,148
12,383,248
12,858,941
12,940,506
12,940,506
12,951,606
12,951,606
13,567,547
13,001,003
13,089,538
19,810,908
20,198,968
20,198,967
20,231,008
20,231,008
20,699,129
20,958,828
21,285,643
22,826,597
23,081,607
23,083,710
34,623,243
34,623,243
34,623,243
34,623,243
34,623,243
34,623,243
35,373,243
35,373,243
38,447,091
0
0
0
0
000038,447,09135,373,24335,373,24334,623,24334,623,24334,623,24334,623,24334,623,24334,623,24323,083,71023,081,60722,826,59721,285,64320,958,82820,699,12920,231,00820,231,00820,198,96720,198,96819,810,90813,089,53813,001,00313,567,54712,951,60612,951,60612,940,50612,940,50612,858,94112,383,24812,367,14812,258,47511,954,88711,470,92711,307,91611,298,48711,150,29510,172,7539,771,4679,673,4969,200,6799,126,2088,809,568
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
246,551,362
246,592,942
66,934,265
74,154,637
117,454,601
125,939,321
126,036,191
114,594,118
114,687,350
113,912,406
113,930,327
113,960,337
113,962,679
118,937,442
118,988,789
134,095,096
0
0
0
0
0000134,095,096118,988,789118,937,442113,962,679113,960,337113,930,327113,912,406114,687,350114,594,118126,036,191125,939,321117,454,60174,154,63766,934,265246,592,942246,551,36200000000000000000000000000
   Treasury Stock0000000000-12,879,453-9,978,045-7,758,373-121,141-121,141-121,141-121,141-121,141-121,141-121,141000-121,141-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092-13,092
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,884,300
8,924,930
8,513,791
8,664,807
8,595,080
8,644,268
8,647,057
8,805,998
8,704,719
142,032
10,491,232
9,420,848
9,379,323
10,842,129
24,042,376
24,154,518
21,406,491
21,837,374
45,620,426
45,731,129
45,811,688
45,191,489
12,116,154
11,922,547
2,584,301
0
0
0
0
00002,584,30111,922,54712,116,15445,191,48945,811,68845,731,12945,620,42621,837,37421,406,49124,154,51824,042,37610,842,1299,379,3239,420,84810,491,232142,0328,704,7198,805,9988,647,0578,644,2688,595,0808,664,8078,513,7918,924,9308,884,30000000000000000000



6.4. Balance Sheets

Currency in KRW. All numbers in thousands.




6.5. Cash Flows

Currency in KRW. All numbers in thousands.




6.6. Income Statements

Currency in KRW. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,878,663
Cost of Revenue-3,421,657
Gross Profit1,457,0061,457,006
 
Operating Income (+$)
Gross Profit1,457,006
Operating Expense-36,317,442
Operating Income-31,438,779-34,860,436
 
Operating Expense (+$)
Research Development7,182,167
Selling General Administrative16,363,470
Selling And Marketing Expenses0
Operating Expense36,317,44223,545,637
 
Net Interest Income (+$)
Interest Income2,420,852
Interest Expense-2,094,578
Other Finance Cost-15,285,622
Net Interest Income15,611,896
 
Pretax Income (+$)
Operating Income-31,438,779
Net Interest Income15,611,896
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-51,151,911-31,438,779
EBIT - interestExpense = -2,094,578
-48,923,631
-46,829,053
Interest Expense2,094,578
Earnings Before Interest and Taxes (EBIT)0-49,057,333
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-51,151,911
Tax Provision--2,940,738
Net Income From Continuing Ops-48,211,174-48,211,174
Net Income-48,923,631
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-15,611,896
 

Technical Analysis of CrystalGenomics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of CrystalGenomics Inc. The general trend of CrystalGenomics Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine CrystalGenomics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CrystalGenomics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2,795 < 3,145 < 3,170.

The bearish price targets are: 2,420 > 2,015.

Tweet this
CrystalGenomics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CrystalGenomics Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CrystalGenomics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CrystalGenomics Inc. The current macd is 29.84.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the CrystalGenomics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for CrystalGenomics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the CrystalGenomics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CrystalGenomics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCrystalGenomics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CrystalGenomics Inc. The current adx is 17.52.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell CrystalGenomics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
CrystalGenomics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CrystalGenomics Inc. The current sar is 2,640.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CrystalGenomics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CrystalGenomics Inc. The current rsi is 49.72. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
CrystalGenomics Inc Daily Relative Strength Index (RSI) ChartCrystalGenomics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CrystalGenomics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the CrystalGenomics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CrystalGenomics Inc Daily Stochastic Oscillator ChartCrystalGenomics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CrystalGenomics Inc. The current cci is -9.86842105.

CrystalGenomics Inc Daily Commodity Channel Index (CCI) ChartCrystalGenomics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CrystalGenomics Inc. The current cmo is -8.22136332.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CrystalGenomics Inc Daily Chande Momentum Oscillator (CMO) ChartCrystalGenomics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CrystalGenomics Inc. The current willr is -48.18181818.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that CrystalGenomics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
CrystalGenomics Inc Daily Williams %R ChartCrystalGenomics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CrystalGenomics Inc.

CrystalGenomics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CrystalGenomics Inc. The current atr is 150.88.

CrystalGenomics Inc Daily Average True Range (ATR) ChartCrystalGenomics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CrystalGenomics Inc. The current obv is 30,310,756.

CrystalGenomics Inc Daily On-Balance Volume (OBV) ChartCrystalGenomics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CrystalGenomics Inc. The current mfi is 69.47.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
CrystalGenomics Inc Daily Money Flow Index (MFI) ChartCrystalGenomics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CrystalGenomics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

CrystalGenomics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CrystalGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.720
Ma 20Greater thanMa 502,571.250
Ma 50Greater thanMa 1002,438.300
Ma 100Greater thanMa 2002,492.700
OpenGreater thanClose2,590.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of CrystalGenomics Inc with someone you think should read this too:
  • Are you bullish or bearish on CrystalGenomics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about CrystalGenomics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CrystalGenomics Inc

I send you an email if I find something interesting about CrystalGenomics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about CrystalGenomics Inc.

Receive notifications about CrystalGenomics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.